Verrica Pharmaceuticals

VRCA on Nasdaq. Market value $61m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 43 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%; 1 of them is pushing for change.

  • Paul B Manning
    Insider or founder
    at least 49.9%
    (filed with 2 related holders)
    Since 25 November 2025
  • Caligan Partners LP
    Activist
    Wants board seats
    at least 10.0%0.0 pts
    (filed with 1 related holder)
    Since 26 December 2025
    What they said

    On December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately.

    Read the filing
  • David Johnson
    Passive investor
    10.0%
    Since 31 December 2024
  • Affinity Healthcare Fund, LP
    Passive investor
    5.5%
    Since 25 November 2025
  • Dellora Investments LP
    Passive investor
    at least 5.2%
    (filed with 1 related holder)
    Since 30 September 2026
  • at least 5.0%−0.5 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • Armistice Capital, LLC
    Passive investor
    at least 5.0%−1.8 pts
    (filed with 1 related holder)
    Since 31 December 2025
  • Perceptive Advisors LLC
    Passive investor
    Sold down below 5%
    Since 31 March 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 5 insiders bought $18m of shares on the open market.

  • Rosenberg Noah L.
    CMO
    Bought
    Date
    18 August 2026
    Shares
    2,030
    Price
    $4.92
    Value
    $9,988
  • Kirby John J.
    Interim CFO
    Bought
    Date
    18 August 2026
    Shares
    5,000
    Price
    $4.93
    Value
    $24,650
  • Zawitz David
    Chief Operating Officer
    Bought
    Date
    17 August 2026
    Shares
    6,000
    Price
    $4.98
    Value
    $29,880
  • Rieger Jayson
    CEO and President, Director
    Bought
    Date
    17 August 2026
    Shares
    5,000
    Price
    $4.91
    Value
    $24,550
  • Rosenberg Noah L.
    CMO
    Bought
    Date
    17 August 2026
    Shares
    4,200
    Price
    $4.91
    Value
    $20,622
  • Rieger Jayson
    CEO and President, Director
    Bought
    Date
    14 August 2026
    Shares
    20,000
    Price
    $5.06
    Value
    $101,200
  • Zawitz David
    Chief Operating Officer
    Bought
    Date
    25 November 2025
    Shares
    10,000
    Price
    $4.24
    Value
    $42,400
  • Rieger Jayson
    CEO and President, Director
    Bought
    Date
    25 November 2025
    Shares
    94,311
    Price
    $4.24
    Value
    $399,879
  • Rosenberg Noah L.
    CMO
    Bought
    Date
    25 November 2025
    Shares
    2,357
    Price
    $4.24
    Value
    $9,994
  • Kirby John J.
    Interim CFO
    Bought
    Date
    25 November 2025
    Shares
    3,536
    Price
    $4.24
    Value
    $14,993

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Verrica Pharmaceuticals’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 11 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 4 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Based on the current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
    Show the full paragraph
    The Company has incurred substantial operating losses since inception and expects to continue to incur significant losses for the foreseeable future and may never become profitable. As of September 30, 2026, the Company has an accumulated deficit of $ 360.2 million and cash of $ 14.4 million. The Company has cash outflows from operations of $ 27.5 million for the nine months ended September 30, 2026. On August 3, 2026, the Company entered into a credit agreement (the "PD Credit Agreement") with PD Joint Holdings, LLC Series 2016-B, at which time $ 12.5 million became available and an additional $ 15.0 million will be available to borrow, subject to the satisfaction of certain milestones and customary conditions as well as compliance with specified covenants. On September 17, 2026, the Company borrowed the available $ 12.5 million under the terms of the PD Credit Agreement. On October 22, 2026, the Company achieved the specified milestones, and the additional $ 15 million became available to borrow, bringing total availability under the PD Credit Agreement to $ 27.5 million, of which $ 12.5 million has been funded. Based on the current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial statements are issued. The Company plans to address the conditions that raise substantial doubt regarding its ability to continue as a going concern by, among other things, borrowing additional amounts available under the PD Credit Agreement and obtaining additional funding through equity offerings, debt financing, collaborations, strategic alliances and/or licensing arrangements. The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the carrying amounts and classification of recorded assets, liabilities and reported expenses that might result should the Company be unable to continue as a going concern. See Note 9 for additional information regarding the PD Credit Agreement.

    From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.